文献速递乳腺癌

免疫组化检测雌激素受体状态在预测乳腺癌辅助内分泌治疗反应方面优于配体结合法

Estrogen Receptor Status by Immunohistochemistry Is Superior to the Ligand-Binding Assay for Predicting Response to Adjuvant Endocrine Therapy in Breast Cancer.
PubMed 文献 · J Clin Oncol · 2023-01-01

本研究在1982例原发性乳腺癌中比较免疫组化(IHC)与配体结合法(LBA)检测雌激素受体(ER)状态预测临床结局的能力。IHC评分大于2定义为ER阳性,与LBA符合率86%。在接受辅助内分泌治疗的患者中,IHC评估的ER状态预测无病生存优于LBA,预测总生存两者相当。

要点

  • IHC评分大于2(对应1%至10%弱阳性细胞)定义为ER阳性,基于无病生存的单因素切点分析。
  • IHC与LBA检测ER状态的符合率为86%,IHC判定71%的肿瘤为ER阳性。
  • 接受辅助内分泌治疗患者中,IHC评估ER状态预测无病生存优于LBA(HR 0.474 vs 0.707)。

核心结论

  • IHC在评估原发性乳腺癌ER状态方面优于LBA,因其更简便、安全、便宜,且预测辅助内分泌治疗反应的能力相当或更好。

研究设计与样本

  • 在1982例原发性乳腺癌中,用抗体6F11和标准方法对福尔马林固定石蜡包埋组织切片进行IHC评估ER状态,并与同批肿瘤的LBA结果及临床结局比较。

主要发现

  • IHC评分大于2(对应低至1%至10%弱阳性细胞)定义为ER阳性,基于所有可能评分与接受任何辅助内分泌治疗患者无病生存的单因素切点分析。
  • 按此定义,IHC判定71%的肿瘤为ER阳性,与LBA的符合率为86%。
  • 在接受辅助内分泌治疗单独治疗的患者多因素分析中,IHC评估的ER状态预测无病生存优于LBA(HR 0.474,P=0.0008 vs HR 0.707,P=0.3214)。
  • 在同一多因素分析中,IHC与LBA评估的ER状态预测总生存相当(HR 0.379,P=0.0001 vs HR 0.381,P=0.0003)。

关键数值与推荐

  • IHC评分大于2(对应低至1%至10%弱阳性细胞)定义为ER阳性。
  • IHC判定ER阳性率为71%,与LBA符合率86%。
  • 接受辅助内分泌治疗患者中,IHC评估ER状态预测无病生存的HR为0.474(P=0.0008),LBA为0.707(P=0.3214)。
  • 接受辅助内分泌治疗患者中,IHC评估ER状态预测总生存的HR为0.379(P=0.0001),LBA为0.381(P=0.0003)。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Immunohistochemistry (IHC) is a newer technique for assessing the estrogen receptor (ER) status of breast cancers, with the potential to overcome many of the shortcomings associated with the traditional ligand-binding assay (LBA). The purpose of this study was to evaluate the ability of ER status determination by IHC, compared with LBA, to predict clinical outcome-especially response to adjuvant endocrine therapy-in a large number of patients with long-term clinical follow-up. PATIENTS AND METHODS: ER status was evaluated in 1,982 primary breast cancers by IHC on formalin-fixed paraffin-embedded tissue sections, using antibody 6F11 and standard methodology. Slides were scored on a scale representing the estimated proportion and intensity of positive-staining tumor cells (range, 0 to 8). Results were compared with ER values obtained by the LBA in the same tumors and to clinical outcome. RESULTS: An IHC score of greater than 2 (corresponding to as few as 1% to 10% weakly positive cells) was used to define ER positivity on the basis of a univariate cut-point analysis of all possible scores and disease-free survival (DFS) in patients receiving any adjuvant endocrine therapy. Using this definition, 71% of all tumors were determined to be ER-positive by IHC, and the level of agreement with the LBA was 86%. In multivariate analyses of patients receiving adjuvant endocrine therapy alone, ER status determined by IHC was better than that determined by the LBA at predicting improved DFS (hazard ratios/P = 0.474/.0008 and 0.707/.3214, respectively) and equivalent at predicting overall survival (0.379/.0001 and 0.381/.0003, respectively). CONCLUSION: IHC is superior to the LBA for assessing ER status in primary breast cancer because it is easier, safer, and less expensive, and has an equivalent or better ability to predict response to adjuvant endocrine therapy.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Harvey JM, Clark GM, Osborne CK, et al. Estrogen Receptor Status by Immunohistochemistry Is Superior to the Ligand-Binding Assay for Predicting Response to Adjuvant Endocrine Therapy in Breast Cancer. J Clin Oncol. 2023. PMID: 36827742. doi:10.1200/JCO.22.02500

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。